Candesartan and Candesartan/ Hydrochlorothiazide in the treatment of patients with hypertension and LVH - CandLE

Study identifier:NIS-CGE-ATA-2007/2

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Candesartan and Candesartan/ Hydrochlorothiazide in the treatment of patients with essential hypertension and a concomitant disease left ventricular hypertrophy

Medical condition

essential hypertension

Phase

Healthy volunteers

Study drug

Sex

Unmapped

Actual Enrollment

686

Study type

Observational

Age

None - None

Date

Study Start Date: 01 Jan 2007

Primary Completion Date: -

Study Completion Date: 01 Oct 2007

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2008 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
1 Patient with essential hypertension and LVH under treatment with candesartan or candesartan HCT	-

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Germany

49 4103 7083650

andrea.pahor@astrazeneca.com

Investigators

Principal Investigator

F. Sonntag

Cardiologist, Henstedt-Ulzburg